Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors Read more
Amgen And Allergan’s MVASI (bevacizumab-awwb) And KANJINTI (trastuzumab-anns) Now Available In The United States Read more
FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections Read more
Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio Read more
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101) Read more
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury Read more
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility Read more